These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25710958)

  • 1. Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
    Zanetti M
    J Immunol; 2015 Mar; 194(5):2049-56. PubMed ID: 25710958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
    Tran E; Turcotte S; Gros A; Robbins PF; Lu YC; Dudley ME; Wunderlich JR; Somerville RP; Hogan K; Hinrichs CS; Parkhurst MR; Yang JC; Rosenberg SA
    Science; 2014 May; 344(6184):641-5. PubMed ID: 24812403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy: targeting the difference.
    Koh S; Bertoletti A
    J Hepatol; 2014 Nov; 61(5):1175-7. PubMed ID: 24993529
    [No Abstract]   [Full Text] [Related]  

  • 4. Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers.
    Miamen AG; Gustafson MP; Roberts LR
    Hepatology; 2014 Dec; 60(6):2121-4. PubMed ID: 25220571
    [No Abstract]   [Full Text] [Related]  

  • 5. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
    Koido S; Kan S; Yoshida K; Yoshizaki S; Takakura K; Namiki Y; Tsukinaga S; Odahara S; Kajihara M; Okamoto M; Ito M; Yusa S; Gong J; Sugiyama H; Ohkusa T; Homma S; Tajiri H
    Anticancer Res; 2014 Nov; 34(11):6353-61. PubMed ID: 25368235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA.
    Junking M; Grainok J; Thepmalee C; Wongkham S; Yenchitsomanus PT
    Tumour Biol; 2017 Oct; 39(10):1010428317733367. PubMed ID: 29034817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.
    Carapeto F; Bozorgui B; Shroff RT; Chagani S; Solis Soto L; Foo WC; Wistuba I; Meric-Bernstam F; Shalaby A; Javle M; Korkut A; Kwong LN
    Hepatology; 2022 Feb; 75(2):297-308. PubMed ID: 34510503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
    Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
    J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
    Gbolahan O; Hashemi-Sadraei N; O'Neil B
    J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of FOXP3 inhibits invasion and immune escape in cholangiocarcinoma.
    Ma C; Peng C; Lu X; Ding X; Zhang S; Zou X; Zhang X
    Biochem Biophys Res Commun; 2015 Mar; 458(2):234-9. PubMed ID: 25623530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholangiocarcinoma.
    Krasinskas AM
    Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab].
    Kan N; Yoshikawa K; Matsushita N; Fujii T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1759-61. PubMed ID: 24393913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma.
    Min JK; Kim JM; Li S; Lee JW; Yoon H; Ryu CJ; Jeon SH; Lee JH; Kim JY; Yoon HK; Lee YK; Kim BH; Son YS; Choi HS; Lim NK; Kim DG; Hong HJ
    Clin Cancer Res; 2010 Jul; 16(14):3571-80. PubMed ID: 20501614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.